Company

SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals develops and commercializes treatments for advanced solid tumors.

About

Founded in 1989 and based in Foster City, US, SciClone Pharmaceuticals develops and commercializes biopharmaceutical products for advanced solid tumors. Its flagship product, Zadaxin (Thymalfasin), is designed to enhance immune response. The company went public on the Hong Kong Stock Exchange on March 3, 2021, raising HKD 2039.5 million. CEO Friedhelm Blobel leads the company.

3Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in